4T1细胞成瘤的乳腺癌小鼠模型临床转化过程中的几个问题

Several problems in clinical transformation of 4T1 cell tumorigenic breast cancer mouse model

动物实验是新化合物向临床转化的基础过程,也是评价其安全性和有效性的关键步骤,因此,合理的剂量设置、动物模型构建与适宜的给药方式是保证实验数据可靠的前提。但是在科学研究的实践中,研究者在选用动物实验条件等方面并没有形成统一标准,使药效评价出现偏差,不能有效促进新化合物向临床的转化。鉴于此种情况,笔者仅以顺铂参与的使用4T1细胞构建的异体移植瘤模型为例,来探讨铂类化合物治疗三阴性乳腺癌(triple negative breast cancer,TNBC)的药效学研究中动物实验存在的问题与可能的解决方案,从而使动物实验更好的为临床转化服务。

Animal experiments not only serve as a basic process of the clinical transformation of new compounds,but also a key step in evaluating the safety and effectiveness of new drugs.Therefore,reasonable dose setting,animal model construction,and appropriate administration method are prerequisites to ensure reliable experimental data.However,in practice,scientific researchers have not formed a unified standard for the selection of animal experimental conditions,leading to deviations in efficacy evaluations and failure to effectively promote the transformation of new compounds into clinical practice.In view of this situation,the author takes the allogeneic tumor model constructed by 4 T1 cells with the participation of cisplatin as an example to explore problems and possible solutions in the pharmacodynamic study of platinum compounds for the treatment of triple negative breast cancer.It is our hope that such findings will facilitate animal experiments that better serve clinical transformation.